Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Synairgen (SYNG)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.85 +0.45    +7.03%
05:03:46 - Real-time Data. Currency in GBP ( Disclaimer )
Type:  Equity
Market:  United Kingdom
ISIN:  GB00B0381Z20 
SEDOL:  B0381Z2
  • Volume: 63,934
  • Bid/Ask: 6.00 / 6.98
  • Day's Range: 6.31 - 6.85
Synairgen 6.85 +0.45 +7.03%

LON:SYNG Financials

 
A brief overview of the LON:SYNG financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Synairgen over time.

Synairgen plc reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was GBP 4.75 million compared to GBP 12.41 million a year ago. Basic loss per share from continuing operations was GBP 0.0236 compared to GBP 0.0616 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

SYNG Income Statement

Gross margin TTM -
Operating margin TTM 0%
Net Profit margin TTM 0%
Return on Investment TTM -47.36%
 Total Revenue  Net Income
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Revenue
Gross Profit
Operating Income -3.15 -3.15 -7 -7
Net Income -2.62 -2.62 -6.2 -6.2

SYNG Balance Sheet

Quick Ratio MRQ 3.88
Current Ratio MRQ 6.77
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Assets 23.53 23.53 29.54 29.54
Total Liabilities 3.25 3.25 4.63 4.63
Total Equity 20.28 20.28 24.92 24.92

SYNG Cash Flow Statement

Cash Flow/Share TTM -0.02
Revenue/Share TTM -
Operating Cash Flow  23.63%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 0.768 0.768 -7.91 -7.91
Cash From Investing Activities -1.82 -1.82 0.008 0.008
Cash From Financing Activities 0 0 0 0
Net Change in Cash -1.05 -1.05 -7.9 -7.9
* In Millions of GBP (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SYNG Comments

Write your thoughts about Synairgen
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Phil Ainge
ThisIsTheWay Aug 24, 2021 9:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
looks like SNG are writing the P3 protocol... waiting for an RNS to confirm
Graham Rogers
Graham Rogers Jun 16, 2021 12:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
finally its starting waiting for confirmation!!!
Phil Ainge
ThisIsTheWay May 04, 2021 6:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
wish I was just buying in at these prices!
Graham Rogers
Graham Rogers May 03, 2021 10:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Trial results are very good, market makers have got this wrong!! Dont know what more i can say!
Jig shares
Jig shares Apr 30, 2021 11:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nuts fall today...I'm out.
Jig shares
Jig shares Apr 30, 2021 3:23AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.globenewswire.com/news-release/2021/04/30/2220373/0/en/Synairgen-announces-data-from-Home-Cohort-of-SG016-Phase-II-trial-of-inhaled-interferon-beta-in-COVID-19-patients-and-encouraging-combined-data-for-whole-SG016-trial.html
Jig shares
Jig shares Apr 26, 2021 3:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anyone have any news on this?
Phil Ainge
ThisIsTheWay Feb 12, 2021 7:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
looks like some good news may be coming...
Phil Ainge
ThisIsTheWay Feb 03, 2021 6:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Graham, a lot of SYNG's work is in trial phases and there tends to be not much movement then an increase when a trial is underway. I hope that we will see more significant moves upwards once trials prove successful. It looks like its going in the right direction so I'm holding for now.
Graham Rogers
Graham Rogers Feb 03, 2021 6:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thanks for response, i knew pretty much what you've said there phase 3 seems very interesting with aniti viral inhaler, im holding long term.
Graham Rogers
Graham Rogers Jan 25, 2021 2:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anyone's thoughts on this seen it mentioned repeatedly yet not taken off, also huge development into antiviral drugs!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email